Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) Loss Submission Form

Kuznick Law is investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ).  Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.